Author

John A. Levi

Observed names: J A Levi, J Levi, J. A. LEVI, J. A. Levi, J. Levi, J.A. Levi, JOHN A. LEVI, John A Levi, John Levi

Observed institutions: University of Maryland, Baltimore, The University of Sydney, University of Maryland Medical Center, Royal Adelaide Hospital, The Royal Melbourne Hospital, Ludwig Cancer Research, Royal Prince Alfred Hospital, Royal North Shore Hospital, Concord Repatriation General Hospital, Peter MacCallum Cancer Centre, Southampton General Hospital, Princess Alexandra Hospital, Sir Charles Gairdner Hospital, Sydney Hospital, Canberra Hospital, Westmead Hospital, St Vincent's Hospital Melbourne, St Vincent's Hospital Sydney, Prince of Wales Hospital, Ludwig Cancer Research, Northern Sydney Local Health District, Ludwig Cancer Research, Clinical Oncological Society of Australia, National Cancer Institute, Ludwig Cancer Research, National Health and Medical Research Council, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Cancer Council Australia

OpenAlex ID: A5110048293

Measuring the quality of life of cancer patients

1981 · Walter O. Spitzer, Annette J. Dobson, et al. · Journal of Chronic Diseases · 1,533

Cancer: Principles and Practice of Oncology

1987 · John A. Levi · Pathology · 404

Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer

1999 · James F. Bishop, Joanna Dewar, et al. · Journal of Clinical Oncology · 209

Fatal pulmonary toxicity resulting from treatment with gemcitabine

1997 · Nick Pavlakis, David R. Bell, et al. · Cancer · 193

PDF

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

1990 · RL Woods, CJ Williams, et al. · British Journal of Cancer · 155

PDF

Mechanism of cis-platinum nephrotoxicity: I. Effects of sulfhydryl groups in rat kidneys.

1980 · J Levi, C Jacobs, et al. · Journal of Pharmacology and Experimental Therapeutics · 146

Metastatic Adenocarcinomas of Unknown Primary Site

1980 · R. L. Woods, R. M. Fox, et al. · New England Journal of Medicine · 144

Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme

2001 · Gavin M. Marx, Nicholas Pavlakis, et al. · Journal of Neuro-Oncology · 127

The predictive value of body protein for chemotherapy-induced toxicity

2000 · Alireza Aslani, Ross C. Smith, et al. · Cancer · 109

Management of Mycosis Fungoides—current Status and Future Prospects

1975 · JOHN A. LEVI, PETER H. WIERNIK · Medicine · 106

Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial

1997 · E. Beller, M. Tattersall, et al. · Annals of Oncology · 85

Changes in body composition during breast cancer chemotherapy with the CMF‐regimen

1999 · A. Aslani, R.C. Smith, et al. · Breast Cancer Research and Treatment · 81

Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial

2010 · Peter S. Grimison, Martin R. Stockler, et al. · JNCI Journal of the National Cancer Institute · 76

Haemolytic anaemia after cisplatin treatment.

1981 · J A Levi, R S Aroney, et al. · BMJ · 76

PDF

Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.

1986 · J A Levi, R M Fox, et al. · Journal of Clinical Oncology · 72

Amodiaquine-induced Agranulocytosis: Toxic Effect of Amodiaquine in Bone Marrow Cultures In Vitro

1973 · D. E. Lind, J. A. Levi, et al. · BMJ · 69

PDF

Patterns of relapse in stages I, II and IIIA Hodgkin's disease: Influence of initial therapy and implications for the future

1977 · John A Levi, Peter H Wiernik, et al. · International Journal of Radiation Oncology*Biology*Physics · 68

PDF

The Mechanism of Neutropenia in Felty's Syndrome

1974 · P. C. Vincent, J. A. Levi, et al. · British Journal of Haematology · 67

A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up.

1988 · J A Levi, D Thomson, et al. · Journal of Clinical Oncology · 66

Cancer patients' attitudes to final events in life: Wish for death, attitudes to cessation of treatment, suicide and euthanasia

1994 · Cathy Owen, Christopher Tennant, et al. · Psycho-Oncology · 61

Improved combination chemotherapy in advanced gastric cancer.

1979 · J A Levi, D N Dalley, et al. · BMJ · 60

PDF

Superior vena caval obstruction: a 10‐year experience

1986 · David R. Bell, Robert L. Woods, et al. · The Medical Journal of Australia · 59

Metastatic adenocarcinoma of unknown primary site. A randomized study of two combination chemotherapy regimens

1987 · S.T. Milliken, M.H.N. Tattersall, et al. · European Journal of Cancer and Clinical Oncology · 56

Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin

1977 · John A. Levi, Peter H. Wiernik, et al. · Medical and Pediatric Oncology · 55

Bleomycin pulmonary toxicity: Its relationship to renal dysfunction

1984 · Angus G. Dalgleish, Robert L. Woods, et al. · Medical and Pediatric Oncology · 54

Works count: 104

Citation count: 5,147

H-index: 35

I10-index: 61